Annual variation in respiratory syncytial virus season and decisions regarding immunoprophylaxis with palivizumab.
Meissner
H Cody
HC
Pediatric Infectious Disease Division, Tufts-New England Medical Center, Tufts University School of Medicine, 750 Washington St, Boston, MA 02111, USA. cmeissner@tufts-nemc.org
Anderson
Larry J
LJ
Pickering
Larry K
LK
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage*; D002648:Child; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D006760:Hospitalization; D006801:Humans; D007223:Infant; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D018113:Respiratory Syncytial Virus, Human; D012307:Risk Factors; D012621:Seasons
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab